GlassScriptPhysician profile
Michal Szpara
NPI 1225551187
$36,959.62
in general payments reported to CMS, 2019-2025
25 companies · $1,278 in 2025
The $1,278 reported for 2025 was more than what 75% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,480 · 2020: $223 · 2021: $5,498 · 2022: $8,418 · 2023: $7,342 · 2024: $12K · 2025: $1,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $2,805 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,087.50 |
| Food and Beverage | $2,804.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $19,027.77 | 2020-2025 | Evos, Tsf, Evos Mini |
| Gramercy Extremity Orthopedics LLC | $13,198.11 | 2021-2025 | |
| Stryker Corporation | $1,169.93 | 2019-2023 | Ortholoc 2 Lapifuse |
| Kairos Surgical INC | $761.66 | 2019 | |
| International Life Sciences | $711.90 | 2023 | |
| Misonix INC | $282.04 | 2021 | |
| Wright Medical Technology, INC. | $266.66 | 2019 | |
| Orthofix Medical, INC. | $265.63 | 2019-2025 | Physio-Stim |
| Polynovo North America LLC | $218.14 | 2024-2025 | Novosorb Btm |
| Integra Lifesciences Corporation | $125.09 | 2019 | |
| Cardiovascular Systems INC. | $122.76 | 2019 | |
| Forma Medical | $114.01 | 2024 | Optimalakin |
| Organogenesis INC. | $113.23 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $103.09 | 2023 | Xarelto |
| Paratek Pharmaceuticals, INC. | $101.30 | 2024-2025 | Nuzyra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $99.87 | 2020 | |
| Bioventus LLC | $63.44 | 2022-2025 | Exogen Ultrasound Bone Healing System |
| Ani Pharmaceuticals, INC. | $51.97 | 2025 | Purified Cortrophin Gel |
| Davol INC. | $35.89 | 2022 | |
| Axogen | $24.98 | 2023 | Avance Nerve Graft |
| Zimmer Biomet Holdings, INC. | $22.98 | 2022 | |
| Medshape, INC. | $20.43 | 2023 | Dynanail Helix, Washer, 15 Mm |
| Bone Support INC. | $20.12 | 2021 | |
| Kci USA, INC. | $19.36 | 2023 | 3m Coban, Promogran Prisma, V.A.C. Dermatac |
| Treace Medical Concepts, INC. | $19.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$90,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michal Szpara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.